Sign in
Taking peoplePhase 3

Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

Key facts

Who runs it
Joincare Pharmaceutical Group Industry Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
177 people, planned
Started
7 Nov 2025
Planned end
15 Apr 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • JKN2301 Dry Suspension
  • Oseltamivir Placebo
  • Oseltamivir
  • JKN2301 Placebo
Record updated
21 January 2026

Who can take part

Age
2 years to 11 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Pediatric patients within the specified age range
  • Clinical presentation consistent with influenza, confirmed by a positive local rapid test or central laboratory PCR test
  • Presentation for treatment within the early symptomatic phase of influenza illness
  • Presence of fever and at least one respiratory symptom
  • Ability to swallow oral suspension
  • Parent/guardian and patient (as age-appropriate) able to provide informed consent/assent

Who cannot take part

  • Presence of a concurrent bacterial infection requiring systemic therapy
  • History of hypersensitivity to any component of the investigational products
  • Use of prohibited medications (including other anti-influenza antivirals) within a specified period prior to enrollment
  • Clinical signs suggestive of severe or complicated influenza infection
  • Significant immunocompromised, or severe/uncontrolled comorbid conditions
  • Any condition that, in the opinion of the investigator, would jeopardize patient safety or compliance with the study protocol
  • requiring inpatient management
  • Recent participation in another interventional clinical trial

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 2 and 11 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.

The 2 groups in the trial

  • JKN2301 + Oseltamivir PlaceboTreatment being tested

    Treatment: JKN2301 Dry Suspension and Oseltamivir Placebo

  • Oseltamivir + JKN2301 PlaceboExisting treatment, for comparison

    Treatment: Oseltamivir and JKN2301 Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza
Criteria questions
Built from NCT07357051, who can take part
Record updated
21 January 2026